- InVivo Therapeutics Announces Froedtert & the Medical College of Wisconsin as New Clinical Trial Site for Neuro-Spinal Scaffold
- InVivo Therapeutics Appoints Lorianne Masuoka, MD as Chief Medical Officer
- InVivo Therapeutics Announces $12 Million Registered Direct Offering
- InVivo Therapeutics Announces Enrollment of Second Subject in Pilot Spinal Cord Injury Trial
- InVivo Therapeutics Reports Three-Month Update of First Acute Spinal Cord Injury Subject Implanted with Neuro-Spinal Scaffold
Developing Technology For The Treatment of Spinal Cord Injuries
InVivo Therapeutics Corporation is developing and intends to commercialize groundbreaking technologies for the treatment of spinal cord injuries (SCI). InVivo intends to leverage its platform technology to deliver several products to the market.